CCL21 Cancer Immunotherapy
Cancer, a major health problem, affects 12 million people worldwide every year. With surgery and chemo-radiation the long term survival rate for the majority of cancer patients is dismal. Thus novel treatments are urgently needed. Immunotherapy, the harnessing of the immune system to destroy cancer...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2014-05-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2072-6694/6/2/1098 |
| _version_ | 1797763300893655040 |
|---|---|
| author | Yuan Lin Sherven Sharma Maie St. John |
| author_facet | Yuan Lin Sherven Sharma Maie St. John |
| author_sort | Yuan Lin |
| collection | DOAJ |
| description | Cancer, a major health problem, affects 12 million people worldwide every year. With surgery and chemo-radiation the long term survival rate for the majority of cancer patients is dismal. Thus novel treatments are urgently needed. Immunotherapy, the harnessing of the immune system to destroy cancer cells is an attractive option with potential for long term anti-tumor benefit. Cytokines are biological response modifiers that stimulate anti-tumor immune responses. In this review, we discuss the anti-tumor efficacy of the chemotactic cytokine CCL21 and its pre-clinical and clinical application in cancer. |
| first_indexed | 2024-03-12T19:39:38Z |
| format | Article |
| id | doaj.art-a5658b73dbf44f59b5eec22079ec2cdc |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T19:39:38Z |
| publishDate | 2014-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-a5658b73dbf44f59b5eec22079ec2cdc2023-08-02T03:55:15ZengMDPI AGCancers2072-66942014-05-01621098111010.3390/cancers6021098cancers6021098CCL21 Cancer ImmunotherapyYuan Lin0Sherven Sharma1Maie St. John2Department of Head and Neck Surgery, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095, USAJonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095, USADepartment of Head and Neck Surgery, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095, USACancer, a major health problem, affects 12 million people worldwide every year. With surgery and chemo-radiation the long term survival rate for the majority of cancer patients is dismal. Thus novel treatments are urgently needed. Immunotherapy, the harnessing of the immune system to destroy cancer cells is an attractive option with potential for long term anti-tumor benefit. Cytokines are biological response modifiers that stimulate anti-tumor immune responses. In this review, we discuss the anti-tumor efficacy of the chemotactic cytokine CCL21 and its pre-clinical and clinical application in cancer.http://www.mdpi.com/2072-6694/6/2/1098CCL21cancer immunotherapydendritic cellpolymerT cell |
| spellingShingle | Yuan Lin Sherven Sharma Maie St. John CCL21 Cancer Immunotherapy Cancers CCL21 cancer immunotherapy dendritic cell polymer T cell |
| title | CCL21 Cancer Immunotherapy |
| title_full | CCL21 Cancer Immunotherapy |
| title_fullStr | CCL21 Cancer Immunotherapy |
| title_full_unstemmed | CCL21 Cancer Immunotherapy |
| title_short | CCL21 Cancer Immunotherapy |
| title_sort | ccl21 cancer immunotherapy |
| topic | CCL21 cancer immunotherapy dendritic cell polymer T cell |
| url | http://www.mdpi.com/2072-6694/6/2/1098 |
| work_keys_str_mv | AT yuanlin ccl21cancerimmunotherapy AT shervensharma ccl21cancerimmunotherapy AT maiestjohn ccl21cancerimmunotherapy |